Martin Elaine Phillips

US Patent:

20040197875, Oct 7, 2004

Filed:

Nov 26, 2003

Appl. No.:

10/721997

Inventors:

Hans-Peter Hauser - Marburg, DE
Thomas Weimer - Gladenbach, DE
Martin Phillips - Wayne PA, US

International Classification:

C12P021/04
C07H021/04
C07K014/745

US Classification:

435/069600, 435/320100, 435/325000, 530/384000, 536/023500

Abstract:

Modified human factor VIII cDNA wherein mutations are inserted either in the wild-type factor VIII cDNA or in a factor VIII cDNA in which the B-domain is partially or completely deleted and may be replaced by a DNA linker segment and A) one or several codons of the human factor VIII cDNA which are not identical with the corresponding codon in the same position of the porcine factor VIII cDNA are substituted by a different codon in such a way that when the human sequence contains a codon for a neutral amino acid whereas the porcine sequence contains a codon for a charged amino acid then a codon for an amino acid with the same charge as found in the porcine sequence is introduced into the human sequence; when the human sequence contains a codon for a charged amino acid whereas the porcine sequence contains a codon for a neutral amino acid then a codon for a neutral amino acid or a codon for an amino acid of the opposite charge is introduced into the human sequence, when the human sequence contains a codon for a charged amino acid whereas the porcine sequence contains a codon for an amino acid with the opposite charge then a codon for an amino acid with the opposite charge is introduced into the human sequence or B) one or several codons for a charged amino acid which are found in the FVIII cDNA of a hemophilic patient are replaced by a codon for an amino acid of the opposite charge.

US Patent:

20220340655, Oct 27, 2022

Filed:

Sep 16, 2020

Appl. No.:

17/640538

Inventors:

- Bryn Mawr PA, US
Martin PHILLIPS - Bryn Mawr PA, US

International Classification:

C07K 16/24
C12N 15/63

Abstract:

The disclosure relates to antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248. The disclosure further relates to methods for making the antibodies, and to methods of use of the antibodies including methods of treatment for inflammatory and/or fibrotic diseases Dose response and disorders.

US Patent:

20220324957, Oct 13, 2022

Filed:

Sep 16, 2020

Appl. No.:

17/640544

Inventors:

- Bryn Mawr PA, US
Martin PHILLIPS - Bryn Mawr PA, US

International Classification:

C07K 16/24
A61P 29/00

Abstract:

The disclosure relates to methods of use in renal diseases and disorders of antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248 and are useful for treating inflammatory and fibrotic renal disorders.

US Patent:

20230019680, Jan 19, 2023

Filed:

Sep 6, 2022

Appl. No.:

17/929976

Inventors:

- Bryn Mawr PA, US
Martin PHILLIPS - Bryn Mawr PA, US

International Classification:

C07K 16/24
A61P 37/08
A61P 11/00
A61P 29/00
A61P 11/06

Abstract:

The disclosure relates to antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248. The disclosure further relates to methods for making the antibodies, and to methods of use of the antibodies including methods of treatment for inflammatory and/or fibrotic diseases and disorders.

US Patent:

20210079084, Mar 18, 2021

Filed:

Sep 16, 2020

Appl. No.:

17/022465

Inventors:

- Bryn Mawr PA, US
Martin PHILLIPS - Bryn Mawr PA, US

International Classification:

C07K 16/24
A61P 37/08
A61P 11/00
A61P 29/00
A61P 11/06

Abstract:

The disclosure relates to antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248. The disclosure further relates to methods for making the antibodies, and to methods of use of the antibodies including methods of treatment for inflammatory and/or fibrotic diseases and disorders.

US Patent:

20200255372, Aug 13, 2020

Filed:

Sep 20, 2019

Appl. No.:

16/578047

Inventors:

- Ann Arbor MI, US
Martin Douglas Phillips - Bryn Mawr PA, US
Robert Matunas - East Windsor NJ, US
Herman Chen - Madison CT, US
Aimesther Betancourt - Montréal, CA
Charles Uzarama - Laval, CA
Roch Thibert - Ville Mont-Royal, CA

International Classification:

C07C 275/28
C07C 273/18
A61K 31/17
A61K 9/20
A61K 9/50

Abstract:

A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

US Patent:

20190282583, Sep 19, 2019

Filed:

Jun 6, 2019

Appl. No.:

16/433543

Inventors:

- Sudbury MA, US
Martin Phillips - Bryn Mawr PA, US
Robert Linke - Sudbury MA, US

International Classification:

A61K 31/53
A61P 25/30
A61K 31/519
A61K 31/506
A61K 31/4196
A61K 45/06
A61K 31/4168
A61K 31/343
A61K 31/138
A61K 31/496
A61K 31/4188

Abstract:

The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the HPA axis like an addiction to a substance (e.g., cocaine, amphetamines, methamphetamine, methylphenidate, heroin, coedine, hydrocodone, nicotine, alcohol, prescription medication (e.g., Percodan, Percoset), marijuana, tobacco, methadone, food), addiction to an activity (e.g., gambling, sex, eating), substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, posttraumatic stress syndrome, borderline personality disorder, disruptive behavior disorders, ADHD, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders (e.g., Prader Willi Syndrome), obesity, depression, menopause, prementsrual syndrome (PMS), obsessive compulsive disorder (OCD), social anxiety, generalized anxiety disorder, dysthymia, or schizophrenia.

US Patent:

20180185375, Jul 5, 2018

Filed:

Jun 22, 2016

Appl. No.:

15/739005

Inventors:

- Sudbury MA, US
Martin Phillips - Bryn Mawr PA, US
Robert Linke - Sudbury MA, US

Assignee:

Embera Neurotherapeutics, Inc. - Sudbury MA

International Classification:

A61K 31/53
A61K 31/519
A61K 31/4196
A61K 31/4188
A61K 31/343
A61K 31/138
A61K 31/496
A61K 31/506
A61K 31/4168
A61P 25/30

Abstract:

The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the HPA axis like an addiction to a substance (e.g., cocaine, amphetamines, methamphetamine, methylphenidate, heroin, codeine, hydrocodone, nicotine, alcohol, prescription medication (e.g., Percodan, Percoset), marijuana, tobacco, methadone, food), addiction to an activity (e.g., gambling, sex, eating), substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, posttraumatic stress syndrome, borderline personality disorder, disruptive behavior disorders, ADHD, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders (e.g., Prader Willi Syndrome), obesity, depression, menopause, premenstrual syndrome (PMS), obsessive compulsive disorder (OCD), social anxiety, generalized anxiety disorder, dysthymia, or schizophrenia.